Bosentan: profile and news

Myogen Reports 2005 Results  06 Mar 2006
...line results of AMB-222, an open-label trial in which ambrisentan was administered to 36 PAH patients who had previously discontinued bosentan, sitaxsentan or ... - Business Wire (press release),

Deconstructing Myogen's market cap  06 Mar 2006
They found it superior to PAH market-leader Actelion's Tracleer (bosentan), which generated revenue for Actelion of $350 million in the first nine months of ... - Nature.com (subscription),

FDA MedWatch - Tracleer (Bosentan): Recommended Dosage Adjustment ...  Mar 2, 2006
BETHESDA, MD -- March 2, 2006 -- Actelion and FDA notified healthcare professionals of changes to the Tracleer (bosentan) prescribing information based on ... - DG News

FDA and Actelion Pharmaceuticals Issue ‘Reminder’ of ...  Mar 3, 2006
...www.fda.gov/medwatch/safety/2006/TracleerPI_012006.pdf) for the drug that were based on postmarketing reports of hepatotoxicity in Tracleer (bosentan) patients ... - Newsinferno.com,

(PZ) Actelion Announces Full Year 2005 Financial Results  Feb 22, 2006
The results showed that bosentan treatment decreased pulmonary vascular resistance and improved exercise capacity without a worsening in oxygen saturation. ... - Houston Chronicle,

Actelion Announces Full Year 2005 Financial Results  Feb 23, 2006
Further data demonstrates unique clinical features of Tracleer® (bosentan) In mid-July 2005, Actelion reported top-line results of BREATHE-5, the first ever ... - PharmaLive.com (press release),

Myogen Reports Positive Top Line Results for Ambrisentan LFT ...  Feb 13, 2006
...the AMB-222 study, an open-label study of ambrisentan in patients with pulmonary arterial hypertension (PAH) who have previously discontinued bosentan and/or ... - PR Newswire (press release),

Encysive Pharmaceuticals Reports Fourth Quarter and Year End 2005 ...  Mar 1, 2006
The Company announced interim results from its ongoing STRIDE-2X long term study evaluating Thelin(TM) and bosentan in PAH patients. ... - Webbolt Business News (subscription),

Myogen posts positive ambrisentan results  Feb 14, 2006
...top line results from an open-label study of ambrisentan in patients with pulmonary arterial hypertension who have previously discontinued bosentan and/or ... - Pharmaceutical Business Review

Actelion Ltd.: Bosentan Studies In Pulmonary Fibrosis Show No ...  Nov 27, 2005
28, 2005 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) (Other OTC:ALIOF) today announced that in the BUILD program with bosentan (Tracleer(R)) in patients suffering ... - PrimeZone (press release),

ACR Poster Presentation Highlights Clinical Data about Bosentan In ...  Nov 22, 2005
...at the American College of Rheumatology (ACR) of results of RAPIDS-2, a placebo-controlled randomized study that evaluated bosentan (Tracleer ® ) in ... - DG News

Bosentan Studies in Pulmonary Fibrosis Show No Effect on Primary ...  Nov 28, 2005
ALLSCHWIL, SWITZERLAND - 28 November 2005 - Actelion Ltd (SWX: ATLN) today announced that in the BUILD program with bosentan (Tracleer®) in patients suffering ... - PharmaLive.com (press release),

Benefits of Revatio in patients with pulmonary arterial ...  Dec 5, 2005
...to improve exercise ability. The efficacy of Revatio has not been evaluated in patients currently on bosentan therapy. The use of ... - Xagena.it,

Swiss shares higher midafternoon tracking Wall St led by Swiss Re ...  Nov 28, 2005
Among mid-caps, Actelion plunged 12.48 pct or 18.10 sfr to 126.90, following disappointing results from a study of main growth-driver drug Tracleer/Bosentan. ... - Forbes

Euroshares higher midday as Wall St seen making new gains, oil ...  Nov 28, 2005
...price. Actelion tumbled 12.9 pct following disappointing results from a study of main growth-driver drug Tracleer/Bosentan. WestLB ... - Forbes

Swiss shares close markedly lower tracking Wall Street, led by ...  Nov 28, 2005
...smaller stocks, Actelion plunged 12.13 pct or 17.6 sfr to 127.40 sfr, following disappointing results from a study of main growth-driver drug Tracleer/Bosentan ... - Forbes

Viagra Effective Against Deadly Lung Disease  Nov 16, 2005
...professor of cardiology at the University of Bologna. The first was bosentan, he noted. "It is common practice now to start with ... - Forbes

The Effect Of Tracleer™ On Male Fertility with Primary Pulmonary ...  Nov 19, 2005
AST and/or ALT plasma levels greater than 3 times ULN. Hypersensitivity to bosentan or any of the components of the formulation. ... - Community Dispatch (press release)

Impact of bosentan in the treatment of inoperable chronic ...  Sep 20, 2005
...announced today that two abstracts presented today at the European Respiratory Society (ERS) conference showed positive impact of bosentan (Tracleer®) in ... - PharmaLive.com (press release),

Encysive Pharmaceuticals Announces Interim Topline Data From ...  Sep 14, 2005
Nasdaq: ENCY) today announced interim, topline results from its ongoing study, STRIDE-2X, evaluating Thelin(TM) (sitaxsentan sodium) and bosentan in patients ... - PR Newswire (press release),

"Wonder Drugs" May Work Wonders for Pulmonary Arterial ...  Sep 30, 2005
In addition to taking Gleevec, the patient described in the case report continued on his other medications, including Tracleer (bosentan), Ventavis (iloprost ... - MedPage Today,

COPD Link with PH is Rare, Say Doctors  Sep 15, 2005
...prostacyclin), which widens the arteries of the lung and inhibits blood clotting; treprostinil (Remodulin), another prostacyclin; bosentan (Tracleer); inhaled ... - PH Neighborhood,

Actelion Hosts its 3rd Research and Development Day  08 Sep 2005
Line-extension studies for our two marketed products Tracleer(R) (bosentan) and Zavesca(R) (miglustat) will report data in short order until year-end. ... - PrimeZone (press release),

Tracleer Excellence Post Marketing Surveillance Programme -- TRAX ...  Sep 4, 2005
...that two abstracts presented at the European Society of Cardiology (ESC) conference confirm the long-term safety profile of Tracleer(r) (bosentan) in treating ... - ArriveNet (press release),

Encysive Pharmaceuticals Presents Thelin(TM) Data at European ...  Sep 6, 2005
...the ESC Poster Sessions on Sunday, September 4: * "Sitaxsentan Treatment for Patients with Pulmonary Arterial Hypertension (PAH) Failing Bosentan Treatment Due ... - PR Newswire (press release),

FDA Grants Expanded Label for Ventavis  Aug 30, 2005
1) information from the Company's clinical study evaluating the safety of Ventavis used in combination with Actelion's Tracleer® (bosentan) for pulmonary ... - Yahoo News (press release)

Developmental drugs offer new hope for devastating lung disease  Aug 31, 2005
Novel antifibrotic agents in clinical trials, such as interferon-gamma 1b, pirfenidone, bosentan, and etanercept, which inhibit the process of fibrosis may ... - Pharmaceutical Business Review

Selectivity: One of Those Flexible Concepts  Aug 11, 2005
I think.) Examples of the planned category include Tracleer (bosentan), a dual endothelin receptor antagonist for pulmonary hypertension, rupatadine, a dual ... - Corante

FDA Sends Warning Letter to Actelion Over Tracleer Web Page  Jul 26, 2005
Drug Marketing, Advertising, and Communications (DDMAC) has reviewed a product page on the Actelion website (www.actelion.com) for Tracleer® (bosentan) Tablets ... - PharmaLive.com (press release)

Actelion Announces Half-Year Financial Results 2005  Jul 27, 2005
Surveillance -- TRAX PMS - Program) represent the completion of the largest non-interventional study to date of patients treated with bosentan for PAH in daily ... - ArriveNet (press release)

Tracleer Study First Ever to Show Benefits in Eisenmenger's ...  Jul 11, 2005
PRIMEZONE) -- Actelion Ltd (SWX:ATLN) (Other OTC:ALIOF) announced today that in the BREATHE-5 study evaluating the use of Tracleer(r) (bosentan) in pulmonary ... - PrimeZone (press release)

Encysive Files for European Marketing Approval of Thelin  Jul 29, 2005
...elevation in liver enzymes to levels >3 times the upper limit of normal) in the 18-week study, compared to 6% for placebo and 11% for bosentan (Tracleer(R ... - PharmaLive.com (press release)

Actelion says Tracleer aids Eisenmenger's patients  Jul 11, 2005
Tracleer, also known by its chemical name bosentan, accounts for virtually all of the company's revenue and has rivals in Pfizer Inc.'s (PFE.N: Quote, Profile ... - Reuters <**results**>

Tracleer helps PAH patients with scleroderma  Jun 13, 2005
...presented at a European rheumatology conference, Actelion said that data showed that Tracleer, also known by its generic name bosentan, helped patients do ... - Heart Center Online

Viagra Could Be Used To Treat Lung Disease  Jun 8, 2005
...advantages is that "it is simple to give, rather than intravenously or in an injection." The only other drug that can be given orally, Bosentan, can damage the ... - TechNewsWorld

Actelion Launches Tracleer in PAH in Japan  Jun 7, 2005
ALLSCHWIL, Switzerland, June 8, 2005 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) (Other OTC:ALIOF) announced today that Tracleer(r) (bosentan) is now available upon ... - PrimeZone (press release),